Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (24)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Verpooten, G. A.
Right arrow Articles by Broe, M. E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verpooten, G. A.
Right arrow Articles by Broe, M. E. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1992) 7: 931-938
© 1992 European Renal Association-European Dialysis and Transplant Association

research-article

Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients

G. A. Verpooten1, P. C. D'Haese1, J. R. Boelaert2, I. Becaus3, L. V. Lamberts1 and M. E. De Broe1,

1Department of Nephrology of the University of Antwerp Antwerp, Belgium 2Renal Unit Algemeen Ziekenhuis St. Jan, Brugge, Belgium 3Renal Unit Onze-Lieve-Vrouw Kliniek, Aalst, BelgiumAbs

Correspondence and offprint requests to: Correspondence and offprint requests to: Marc E. De Broc, MD, PhD, University of Antwerp, Department of Nephrology-Hypertension, p/a University Hospital Antwerp, Wilrijkstraat 10, B-2650 Edegem/Antwerpen, Belgium

We investigated the pharmacokinetics of desferrioxamine and its chelated compounds aluminoxamine and ferrioxamine in normal volunteers and haemodialysis patients with and without iron overload. Desferrioxamine was administered in a single dose of 30 mg per kg body-weight as a 30-min infusion to five healthy volunteers and to 20 haemodialysis patients (five patients without haemosiderosis and 15 patients with haemosiderosis). The interdialytic half-life of ferrioxamine was 2.2 h in normal volunteers, 13.3 h in dialysis patients without haemosiderosis, and 24.6 h in patients with haemosiderosis. There was no interdialytic elimination of aluminoxamine. In a second study, seven dialysis patientsreceived 5, 10, and 20 mg per kg body-weight desferri-oxamine in a random order with a time interval of 2weeks. The peak serum concentrations after thesedoses were 4.1±2.9, 6.4±2.9, and 10.7±7.1 umol/1for ferrioxamine and 2.8 ±1.5, 3.1 ±1.5, and4.2+ 1.7 umol/1 for aluminoxamine. Thus, a 4-foldincrease in desferrioxamine dosage resulted in a 2.7-fold increase in peak ferrioxamine levels and in onlya 1.5-fold increase in peak aluminoxamine levels. Weconclude that dialysis patients, especially those with haemosiderosis, are exposed to persistently elevatedferrioxamine levels. Weekly doses of 5–10mg/kg of desferrioxamine would be sufficient for aluminiumchelation therapy.

Keywords: aluminoxamine; desferrioxamine; ferrioxamine; iron overload; mucormycosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.